Trial intelligence / Profile preview

BEBT-908 and BEBT-109 in EGFR-TKI–resistant NSCLC

CTR20213331Phase 2Completed

Sponsor

Bibet Pharmaceutical

Start

Dec 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1